In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography
Clinical Pharmacology & Therapeutics2015Vol. 97(6), pp. 565–567
Citations Over TimeTop 15% of 2015 papers
Abstract
Positron emission tomography (PET) can visualize and quantify receptors and other targets in the living human brain, and recent progress in radioligand development has enabled measurement of cannabinoid type-1 (CB1 ) receptors. Cannabinoid CB1 receptors have been implicated in multiple human diseases, such as obesity, mood disorders, and addiction. First in vivo human studies have shown distinctive spatial and temporal alterations in cannabinoid CB1 receptor binding in addictive disorders.
Related Papers
- → Positron Emission Tomography and Computed Tomography versus Positron Emission Tomography–Computed Tomography: Tools for Imaging the Lung(2007)19 cited
- → Biologically Optimized 3-Dimensional In Vivo Predictive Assay-based Radiation Therapy Using Positron Emission Tomography-Computerized Tomography Imaging 1(2003)3 cited
- → Diffuse skeletal uptake on 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan in a patient with acute lymphoblastic leukemia: A typical superscan pattern resembling naf positron emission tomography scan(2019)2 cited
- Clinical applications of 18F fluoro-2-deoxy-D-glucose (FDG) positron emission tomography- computed tomography (PET/CT)(2012)
- → Seeing is believing: in vivo functional real-time imaging of transplanted islets using positron emission tomography (PET)(2006)4 cited